Golden Biotechnology Antroquinonol Granted Orphan Drug Designation by FDA for Treatment of Acute Myeloid Leukemia

Industry News

The U.S. Food and Drug Administration has granted Hocena Orphan Drug Designation (ODD) for the treatment of acute myeloid leukemia (AML).  Hocena, also known as antroquinonol, is the pure compound extracted from Antrodia camphorata (AC), a rare medical fungus that grows naturally inside a native tree species in Taiwan.  Golden Biotech, a biotechnology company based in Taipei, Taiwan holds the patent for compound antroquinonol and is developing it for cancer treatment and prevention.  AML is a rare and fast-growing cancer of the blood plasma cells in the bone marrow.  The company has completed a phase I trial in NSCLC (non-small cell lung cancer) and is currently recruiting for a phase II trial treating NSCLC patients who have failed two lines of anti-cancer therapy.  Hocena received ODD from the FDA for pancreatic cancer earlier this year.


Subscribe to WXPress

Receive our newsletter and information on upcoming events.